Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors

Movement Disorders

Volumn 21, Issue 12, 2006, Pages 2090-2095

  Hill, Michael P ^a   Ravenscroft, Paula ^a   McGuire, Steven G ^a   Brotchie, Jonathan M ^a,d   Crossman, Alan R ^a,b   Rochat, Catherine ^c   Millan, Mark J ^c  

^a Williams House   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

D2 D3 receptors; Dyskinesia; L dopa; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE PLUS LEVODOPA; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; L 741626; S 32504; S 33084; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DYSKINESIA; FEMALE; LOCOMOTION; MALE; MARMOSET; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CALLITHRIX; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; INDOLES; LEVODOPA; MOTOR ACTIVITY; MPTP POISONING; OXAZINES; PIPERIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TIME FACTORS;

EID: 33846443167     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21106     Document Type: Article

References (29)

1. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000;23(Suppl. 10):S2-S7.
2. Rascol O, Fabre N. Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin Neuropharmacol 2001;24:313-323.
3. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2:577-588.
4. Rascol O, Brooks DJ, Korczyn AD, De-Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa: 056 Study Group. N Engl J Med 2000;342:1484-1491.
5. LeWitt PA. New drugs for the treatment of Parkinson's disease. Pharmacotherapy 2000;20(Pt. 2):26S-32S.
6. Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, Lavielle G, Brocco M. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II, functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000;293:1063-1073.
7. Joyce JN, Presgraves S, Renish L, et al. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP +) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole. Exp Neurol 2003;184:393-407.
8. Milian MJ, Brocco M, Papp M, et al. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III, actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. J Pharmacol Exp Ther 2004;309:936-950.
9. Millan MJ, Di Cara B, Hill M, et al. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II, actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. J Pharmacol Exp Ther 2004;309:921-935.
10. Millan MJ, Cussac D, Gobert A, et al. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I, cellular, electrophysiological, and neurochemical profile in comparison with ropinirole. J Pharmacol Exp Ther 2004;309:903-920.
11. Presgraves SP, Borwege S, Milian MJ, Joyce JN. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Exp Neurol 2004;190:157-170.
12. Brocco M, Gobert A, Lavielle G, Dekeyne A, Millan MJ. S33138, a novel and preferential antagonist at dopamine D3 receptors: functional profile in rodent models of the control of negative-cognitive symptoms of schizophrenia. Int J Neuropsychopharm 2004;7(Suppl. 7):S265.
13. Milian MJ, Gobert A, Newman-Tancredi A, et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I, receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000;293:1048-1062.
14. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 1995;10:731-740.
15. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 2001;16:642-650.
16. Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ, Brotchie JM. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp Neurol 2004;188: 128-138.
17. Smith L, De Salvia M, Jenner P, Marsden CD. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Mov Disord 1996; 11:125-135.
18. Maratos EC, Jackson MJ, Pearce RK, Jenner P. Antiparkinsonian activity and dysikinesia risk of ropinirole and L-dopa combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord 2001;16:631-641.
19. Blanchet PJ, Konitsiotis S, Chase TN. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. J Pharmacol Exp Ther 1997;283:794-799.
20. Robinet PM, Bardo MT. Dopamine D3 receptors are involved in amphetamine-induced contralateral rotation in 6-OHDA lesioned rats. Pharmacol Biochem Behav 2001;70:43-54.
21. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 2005;10:917-925.
22. Boulay D, Depoortere R, Oblin A, Sanger DJ, Schoemaker H, Perrault G. Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice. Eur J Pharmacol 2000;391:63-73.
23. Millan MJ, Seguin L, Gobert A, Cussac D, Brocco M. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology (Berl) 2004;174:341-357.
24. Accili D, Fishburn CS, Drago J, et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci U S A 1996;93:1945-1949.
25. Newman-Tancredi A, Cussac D, Brocco M, et al. Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra. Brain Res 2001;920:41-54.
26. Wang Y, Xu R, Sasaoka T, Tonegawa S, Kong UP, Sankoorikal EB. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J Neurosci 2000;20:8305-8314.
27. Baik JH, Picetti R, Saiardi A, et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 1995; 377:424-428.
28. van Kampen JM, Stoessl AJ. Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience 2003;116:307-314.
29. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-767.